ADMA Biologics (ADMA) Stock Analysis & Winston Score

ADMA Biologics makes medicines from human blood plasma to help people whose immune systems don't work well enough to fight infections on their own. Its main product is BIVIGAM, an intravenous immunoglobulin (IVIG) therapy, along with ASCENIV, a specialty IVIG for patients with weakened immune systems. The company sells primarily to hospitals, specialty pharmacies, and clinics across the United States, serving patients with conditions like primary immunodeficiency diseases. ADMA makes money by collecting plasma at its own donor centers, processing it into finished therapies, and selling those products directly to healthcare providers. Operating almost entirely in the US, the company has built a vertically integrated model — meaning it controls plasma collection, manufacturing, and sales — which helps protect margins and supply. With strong gross and operating margins and a growing demand for IVIG therapies, the key growth driver is expanding plasma collection capacity, while the main risk is competition from larger, well-established plasma companies like Grifols and Takeda.